Xuejun Kuang1,2, Jiye Zhu3, Zhao Peng1, Jianjun Wang1,2, Zhigang Chen4. 1. Department of Clinical Medicine, Xiangnan University, Chenzhou, 423000, China. 2. Department of Hepatobiliary Surgery, The Affiliated Hospital of Xiangnan University, Chenzhou, 423000, China. 3. Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, 530023, China. richardabson198@yahoo.com. 4. Department of General Surgery, The First People's Hospital of Changde, Changde, 415003, China.
Abstract
BACKGROUND: Recent studies have demonstrated that transducin (beta)-like 1 X-linked receptor 1 (TBLR1) is involved in tumor progression. However, the exact role and clinical significance of TBLR1 in hepatocellular carcinoma (HCC) are poorly understood. AIM: In this study, we aimed to investigate the expression and clinical significance of TBLR1 in HCC. METHODS: Quantitative polymerase chain reaction and immunohistochemical staining were performed to detect the expression levels of TBLR1 in HCC tissue and adjacent noncancerous tissue (ANT). The relationships between TBLR1 expression and clinicopathological factors were examined in this study. The effects of TBLR1 on epithelial-mesenchymal transition (EMT) of HCC cells were investigated in vitro. RESULTS: The expression levels of TBLR1 were elevated in HCC cell lines. TBLR1 mRNA in HCC tissue was markedly higher (P < 0.001) than that in ANT. High expression of TBLR1 is closely related to serum alpha fetoprotein (P = 0.047), BCLC stage (P < 0.001), maximum size of tumors (P < 0.001), tumor embolus (P < 0.001), and histological grade (P < 0.001). The disease-free survival and overall survival of HCC patients with high expression of TBLR1 were significantly shorter. Furthermore, we found that EMT of HCC cells could be induced by up-regulating TBLR1 and be inhibited by down-regulating TBLR1. ICG-001, the inhibitor of Wnt/β-catenin signaling, could suppress induction of EMT mediated by TBLR1. CONCLUSIONS: Our finding suggested that TBLR1 is likely to be a potential prognostic indicator and therapeutic target for HCC and that TBLR1 may be implicated in EMT of HCC cells.
BACKGROUND: Recent studies have demonstrated that transducin (beta)-like 1 X-linked receptor 1 (TBLR1) is involved in tumor progression. However, the exact role and clinical significance of TBLR1 in hepatocellular carcinoma (HCC) are poorly understood. AIM: In this study, we aimed to investigate the expression and clinical significance of TBLR1 in HCC. METHODS: Quantitative polymerase chain reaction and immunohistochemical staining were performed to detect the expression levels of TBLR1 in HCC tissue and adjacent noncancerous tissue (ANT). The relationships between TBLR1 expression and clinicopathological factors were examined in this study. The effects of TBLR1 on epithelial-mesenchymal transition (EMT) of HCC cells were investigated in vitro. RESULTS: The expression levels of TBLR1 were elevated in HCC cell lines. TBLR1 mRNA in HCC tissue was markedly higher (P < 0.001) than that in ANT. High expression of TBLR1 is closely related to serum alpha fetoprotein (P = 0.047), BCLC stage (P < 0.001), maximum size of tumors (P < 0.001), tumor embolus (P < 0.001), and histological grade (P < 0.001). The disease-free survival and overall survival of HCC patients with high expression of TBLR1 were significantly shorter. Furthermore, we found that EMT of HCC cells could be induced by up-regulating TBLR1 and be inhibited by down-regulating TBLR1. ICG-001, the inhibitor of Wnt/β-catenin signaling, could suppress induction of EMT mediated by TBLR1. CONCLUSIONS: Our finding suggested that TBLR1 is likely to be a potential prognostic indicator and therapeutic target for HCC and that TBLR1 may be implicated in EMT of HCC cells.
Authors: Ho-Geun Yoon; Doug W Chan; Zhi-Qing Huang; Jiwen Li; Joseph D Fondell; Jun Qin; Jiemin Wong Journal: EMBO J Date: 2003-03-17 Impact factor: 11.598
Authors: Terence K Lee; Ronnie T P Poon; Anthony P Yuen; Ming Tat Ling; Wei Kei Kwok; Xiang Hong Wang; Yong Chuan Wong; Xin Yuan Guan; Kwan Man; King Lok Chau; Sheung Tat Fan Journal: Clin Cancer Res Date: 2006-09-15 Impact factor: 12.531
Authors: Michael D Arensman; Donatello Telesca; Anna R Lay; Kathleen M Kershaw; Nanping Wu; Timothy R Donahue; David W Dawson Journal: Mol Cancer Ther Date: 2014-07-31 Impact factor: 6.261
Authors: Valentina Perissi; Aneel Aggarwal; Christopher K Glass; David W Rose; Michael G Rosenfeld Journal: Cell Date: 2004-02-20 Impact factor: 41.582
Authors: Benjamin S Simpson; Niedzica Camacho; Hayley J Luxton; Hayley Pye; Ron Finn; Susan Heavey; Jason Pitt; Caroline M Moore; Hayley C Whitaker Journal: Commun Biol Date: 2020-08-14